Revenue: As of FY2026 Q1, the actual value is USD 186.67 M, beating the estimate of USD 184.48 M.EPS: As of FY2026 Q1, the actual value is USD -0.13, beating the estimate of USD -0.1588.EBIT: As of FY2026 Q1, the actual value is USD -18.92 M.<h4>First Quarter 2026 Financial Highlights</h4>Total RevenueNeoGenomics, Inc. reported a consolidated revenue of $187 million for the first quarter of 2026, an 11% increase year-over-year compared to $168.035 million in the first quarter of 2025. Clinical revenue grew by 14%, including NGS growth of 26%.Net LossThe net loss for the first quarter of 2026 was - $17.106 million, a 34% decrease from the net loss of - $25.923 million in the first quarter of 2025.Adjusted EBITDAAdjusted EBITDA for the first quarter of 2026 was $9.004 million, a 27% increase compared to $7.070 million in the first quarter of 2025.Gross ProfitConsolidated gross profit for the first quarter of 2026 was $80.864 million, a 10% increase from $73.246 million in the first quarter of 2025.Gross Profit MarginThe GAAP consolidated gross profit margin was 43.3% for Q1 2026, compared to 43.6% for Q1 2025. The Adjusted Gross Profit Margin was 46.0% for Q1 2026, down from 46.8% for Q1 2025.Operating ExpensesTotal operating expenses for the first quarter of 2026 were $99.105 million, a 2% decrease from $101.071 million in the first quarter of 2025. This includes General and administrative expenses of $65.741 million, Research and development expenses of $9.534 million, and Sales and marketing expenses of $23.830 million for Q1 2026.Adjusted Net Income/(Loss)Adjusted net income was $1.371 million for Q1 2026, compared to an Adjusted net loss of - $0.459 million in Q1 2025.Cash and Cash EquivalentsCash and cash equivalents and marketable securities totaled $146 million at quarter end. Cash and cash equivalents were $146.143 million as of March 31, 2026, down from $159.618 million as of December 31, 2025.Operating Cash FlowNet cash used in operating activities was - $8.137 million for the three months ended March 31, 2026, an improvement from - $25.327 million for the same period in 2025.Investing ActivitiesNet cash used in investing activities was - $5.000 million for the three months ended March 31, 2026, compared to $3.560 million provided by investing activities in the prior year period.Financing ActivitiesNet cash used in financing activities was - $0.338 million for the three months ended March 31, 2026, compared to $0.949 million provided by financing activities in the prior year period.<h4>Operational Metrics</h4>Clinical Tests PerformedThe number of clinical tests performed, including Pathline, increased by 6.0% to 345,679 in Q1 2026 from 326,163 in Q1 2025. Excluding Pathline, the number of tests performed increased by 2.8% to 335,155.Average Revenue Per Clinical TestAverage revenue per clinical test increased by 7.8% to $495 in Q1 2026 from $459 in Q1 2025. Excluding Pathline tests, average revenue per clinical test increased by 9.2% to $501.Product Launches and CoverageNeoGenomics, Inc. launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which is estimated to address a $20 billion market growing at 30% annually. The company also announced a favorable MolDX coverage decision for PanTracer™ LBx and introduced PanTracer Pro.<h4>Outlook / Guidance</h4>NeoGenomics, Inc. revised its full-year 2026 revenue guidance to a range of $797 million to $803 million, representing a 10% year-over-year increase from 2025. The company expects a net loss between - $63 million and - $50 million, and Adjusted EBITDA guidance is maintained at $55 million to $57 million.

Neogenomics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 186.67 M